Trial Profile
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Ceritinib (Primary) ; Entrectinib (Primary) ; Regorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Jan 2020 Status changed from completed to discontinued.
- 29 May 2019 Status changed from recruiting to completed.
- 20 Dec 2017 Planned End Date changed from 1 Sep 2018 to 30 Sep 2020.